The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.

Claims

20 · 1 independent · depth 4

20 granted claims

›1.independentA method of treating a patient having an injury to or a disorder of an eye, said injury or disorder comprising degeneration of a photoreceptor cell, s…+19

›2.↳ 1The method of claim 1, wherein the polypeptide is attached to a water soluble polymer.d2+1

›4.↳ 1The method of claim 1, wherein the polypeptide is admlnistered as a sustained-release pharmaceutical composition.d2

›5.↳ 1The method of claim 1, wherein the polypeptide is admlnistered as a topical pharmaceutical composition.d2

›6.↳ 1The method of claim 1, wherein the polypeptide is admlnistered as an oral pharmaceutical composition.d2

›7.↳ 1The method of claim 1, wherein the polypeptide is admlnistered as a parenteral pharmaceutical composition.d2

›8.↳ 1The method of claim 1, wherein the polypeptide is admlnistered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.d2+1

›10.↳ 1The method of claim 1, wherein the polypeptide comprises amlno acids 9 to 396 of SEQ ID NO: 2.d2+9

›11.↳ 10The method of claim 10, whercin the polypeptide is attached to a water soluble polymer.d3+1

›13.↳ 10The method of claim 10, wherein the polypeptide is admlnistered as a sustained-releasc pharmaceutical composition.d3

›14.↳ 10The method of claim 10, wherein the polypeptide is admlnistered as a topical pharmaceutical composition.d3

›15.↳ 10The method of claim 10, wherein the polypeptide is admlnistered as an oral pharmaceutical composition.d3

›16.↳ 10The method of claim 10, wherein the polypeptide is admlnistered as a parenteral pharmaceutical composition.d3

›17.↳ 10The method of claim 10, wherein the polypeptide is admlnistered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.d3+1

›20.↳ 10The method of claim 10, wherein the injury or disorder is selected from the group consisting of age-related macular degeneration, diabetic retinopathy…d3

›19.↳ 1The method of claim 1, wherein the injury or disorder is selected from the group consisting of age-related macular degeneration, diabetic retinopathy,…d2

Classifications

6 codes

IPC · International Patent Classification

Section A — Human necessities

A01N25/00
A01N37/18

USPC · US Patent Classification

514/2514/963514/964514/969

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

6.3 y

2,290 days filing → grant

Office actions

after a restriction

Responses

4 RCE

Examiner

Robert Landsman

art unit 1647 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 240 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

Priority

22 Dec 1999

earliest claimed

›Priority documents — 1

Type	Document	Date
provisional	US 60171505 00	22 Dec 1999

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.